ASCO 2022: Trastuzumab Deruxtecan Bests Standard-of-Care Chemotherapy in HER2-Low Metastatic Breast Cancer
Similar benefits were observed in patients with HR-positive and HR-negative disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.